The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | MURANO update: sustained benefit for time-limited VenR & biomarkers for response in CLL
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses the 4-year analysis of the MURANO trial (NCT02005471); this confirmed the sustained benefit of time-limited venetoclax and rituximab (VenR) in relapsed/refractory chronic lymphocytic leukemia (CLL). In addition, he highlights the potential predictive markers for response to VenR in terms of MRD status that genome and exome-wide study revealed. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
